In last trading session, Actinium Pharmaceuticals Inc (AMEX:ATNM) saw 1.69 million shares changing hands with its beta currently measuring 0.02. Company’s recent per share price level of $9.11 trading at $0.51 or 5.93% at ring of the bell on the day assigns it a market valuation of $252.89M. That closing price of ATNM’s stock is at a discount of -4.94% from its 52-week high price of $9.56 and is indicating a premium of 56.09% from its 52-week low price of $4.00. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.63 million shares which gives us an average trading volume of 259.24K if we extend that period to 3-months.
Actinium Pharmaceuticals Inc (AMEX:ATNM) trade information
Upright in the green during last session for gaining 5.93%, in the last five days ATNM remained trading in the green while hitting it’s week-highest on Thursday, 03/21/24 when the stock touched $9.11 price level, adding 2.04% to its value on the day. Actinium Pharmaceuticals Inc’s shares saw a change of 79.33% in year-to-date performance and have moved 45.30% in past 5-day. Actinium Pharmaceuticals Inc (AMEX:ATNM) showed a performance of 36.79% in past 30-days. Number of shares sold short was 1.8 million shares which calculate 8.38 days to cover the short interests.
Actinium Pharmaceuticals Inc (ATNM) estimates and forecasts
Statistics highlight that Actinium Pharmaceuticals Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company added 45.53% of value to its shares in past 6 months, showing an annual growth rate of -50.36% while that of industry is 11.50. Apart from that, the company came lowering its revenue forecast for fiscal year 2024. The company is estimating its revenue growth to decrease by -25.60% in the current quarter and calculating -41.90% decrease in the next quarter. This year revenue growth is estimated to fall -82.50% from the last financial year’s standing.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 35.23% during past 5 years.
ATNM Dividends
Actinium Pharmaceuticals Inc is more likely to be releasing its next quarterly report between March 31 and April 15 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Actinium Pharmaceuticals Inc (AMEX:ATNM)’s Major holders
Insiders are in possession of 2.32% of company’s total shares while institution are holding 26.32 percent of that, with stock having share float percentage of 26.94%. Investors also watch the number of corporate investors in a company very closely, which is 26.32% institutions for Actinium Pharmaceuticals Inc that are currently holding shares of the company. Blackrock Inc. is the top institutional holder at ATNM for having 1.7 million shares of worth $12.6 million. And as of Jun 29, 2023, it was holding 6.29% of the company’s outstanding shares.
The second largest institutional holder is Vanguard Group Inc, which was holding about 1.33 million shares on Jun 29, 2023. The number of shares represents firm’s hold over 4.94% of outstanding shares, having a total worth of $9.9 million.
On the other hand, Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Jun 29, 2023, the former fund manager was holding 0.79 million shares of worth $5.89 million or 2.94% of the total outstanding shares. The later fund manager was in possession of 0.58 million shares on Aug 30, 2023, making its stake of worth around $3.48 million in the company or a holder of 2.14% of company’s stock.
